Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 68

1.

Effective sensitization of temozolomide by ABT-888 is lost with development of temozolomide resistance in glioblastoma xenograft lines.

Clarke MJ, Mulligan EA, Grogan PT, Mladek AC, Carlson BL, Schroeder MA, Curtin NJ, Lou Z, Decker PA, Wu W, Plummer ER, Sarkaria JN.

Mol Cancer Ther. 2009 Feb;8(2):407-14. doi: 10.1158/1535-7163.MCT-08-0854. Epub 2009 Jan 27.

2.

Discordant in vitro and in vivo chemopotentiating effects of the PARP inhibitor veliparib in temozolomide-sensitive versus -resistant glioblastoma multiforme xenografts.

Gupta SK, Mladek AC, Carlson BL, Boakye-Agyeman F, Bakken KK, Kizilbash SH, Schroeder MA, Reid J, Sarkaria JN.

Clin Cancer Res. 2014 Jul 15;20(14):3730-41. doi: 10.1158/1078-0432.CCR-13-3446. Epub 2014 May 16.

3.

Evaluation of poly (ADP-ribose) polymerase inhibitor ABT-888 combined with radiotherapy and temozolomide in glioblastoma.

Barazzuol L, Jena R, Burnet NG, Meira LB, Jeynes JC, Kirkby KJ, Kirkby NF.

Radiat Oncol. 2013 Mar 19;8:65. doi: 10.1186/1748-717X-8-65.

4.

A randomized phase I/II study of ABT-888 in combination with temozolomide in recurrent temozolomide resistant glioblastoma: an NRG oncology RTOG group study.

Robins HI, Zhang P, Gilbert MR, Chakravarti A, de Groot JF, Grimm SA, Wang F, Lieberman FS, Krauze A, Trotti AM, Mohile N, Kee AY, Colman H, Cavaliere R, Kesari S, Chmura SJ, Mehta M.

J Neurooncol. 2016 Jan;126(2):309-16. doi: 10.1007/s11060-015-1966-z. Epub 2015 Oct 27.

5.

Evaluation of Concurrent Radiation, Temozolomide and ABT-888 Treatment Followed by Maintenance Therapy with Temozolomide and ABT-888 in a Genetically Engineered Glioblastoma Mouse Model.

Lemasson B, Wang H, Galbán S, Li Y, Zhu Y, Heist KA, Tsein C, Chenevert TL, Rehemtulla A, Galbán CJ, Holland EC, Ross BD.

Neoplasia. 2016 Feb;18(2):82-9. doi: 10.1016/j.neo.2015.11.014.

6.

ABT-888 confers broad in vivo activity in combination with temozolomide in diverse tumors.

Palma JP, Wang YC, Rodriguez LE, Montgomery D, Ellis PA, Bukofzer G, Niquette A, Liu X, Shi Y, Lasko L, Zhu GD, Penning TD, Giranda VL, Rosenberg SH, Frost DJ, Donawho CK.

Clin Cancer Res. 2009 Dec 1;15(23):7277-90. doi: 10.1158/1078-0432.CCR-09-1245. Epub 2009 Nov 24.

7.

Synergistic cytotoxicity of the poly (ADP-ribose) polymerase inhibitor ABT-888 and temozolomide in dual-drug targeted magnetic nanoparticles.

Muñoz-Gámez JA, López Viota J, Barrientos A, Carazo Á, Sanjuán-Nuñez L, Quiles-Perez R, Muñoz-de-Rueda P, Delgado Á, Ruiz-Extremera Á, Salmerón J.

Liver Int. 2015 Apr;35(4):1430-41. doi: 10.1111/liv.12586. Epub 2014 Jun 3.

PMID:
24821649
8.

ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models.

Donawho CK, Luo Y, Luo Y, Penning TD, Bauch JL, Bouska JJ, Bontcheva-Diaz VD, Cox BF, DeWeese TL, Dillehay LE, Ferguson DC, Ghoreishi-Haack NS, Grimm DR, Guan R, Han EK, Holley-Shanks RR, Hristov B, Idler KB, Jarvis K, Johnson EF, Kleinberg LR, Klinghofer V, Lasko LM, Liu X, Marsh KC, McGonigal TP, Meulbroek JA, Olson AM, Palma JP, Rodriguez LE, Shi Y, Stavropoulos JA, Tsurutani AC, Zhu GD, Rosenberg SH, Giranda VL, Frost DJ.

Clin Cancer Res. 2007 May 1;13(9):2728-37.

9.

The selective poly(ADP-ribose) polymerase-1(2) inhibitor, CEP-8983, increases the sensitivity of chemoresistant tumor cells to temozolomide and irinotecan but does not potentiate myelotoxicity.

Miknyoczki S, Chang H, Grobelny J, Pritchard S, Worrell C, McGann N, Ator M, Husten J, Deibold J, Hudkins R, Zulli A, Parchment R, Ruggeri B.

Mol Cancer Ther. 2007 Aug;6(8):2290-302.

10.

Potentiation of temozolomide cytotoxicity by poly(ADP)ribose polymerase inhibitor ABT-888 requires a conversion of single-stranded DNA damages to double-stranded DNA breaks.

Liu X, Shi Y, Guan R, Donawho C, Luo Y, Palma J, Zhu GD, Johnson EF, Rodriguez LE, Ghoreishi-Haack N, Jarvis K, Hradil VP, Colon-Lopez M, Cox BF, Klinghofer V, Penning T, Rosenberg SH, Frost D, Giranda VL, Luo Y.

Mol Cancer Res. 2008 Oct;6(10):1621-9. doi: 10.1158/1541-7786.MCR-08-0240.

11.

Temozolomide-mediated radiation enhancement in glioblastoma: a report on underlying mechanisms.

Chakravarti A, Erkkinen MG, Nestler U, Stupp R, Mehta M, Aldape K, Gilbert MR, Black PM, Loeffler JS.

Clin Cancer Res. 2006 Aug 1;12(15):4738-46.

12.

The PARP inhibitor, ABT-888 potentiates temozolomide: correlation with drug levels and reduction in PARP activity in vivo.

Palma JP, Rodriguez LE, Bontcheva-Diaz VD, Bouska JJ, Bukofzer G, Colon-Lopez M, Guan R, Jarvis K, Johnson EF, Klinghofer V, Liu X, Olson A, Saltarelli MJ, Shi Y, Stavropoulos JA, Zhu GD, Penning TD, Luo Y, Giranda VL, Rosenberg SH, Frost DJ, Donawho CK.

Anticancer Res. 2008 Sep-Oct;28(5A):2625-35.

13.

The Efficacy of the Wee1 Inhibitor MK-1775 Combined with Temozolomide Is Limited by Heterogeneous Distribution across the Blood-Brain Barrier in Glioblastoma.

Pokorny JL, Calligaris D, Gupta SK, Iyekegbe DO Jr, Mueller D, Bakken KK, Carlson BL, Schroeder MA, Evans DL, Lou Z, Decker PA, Eckel-Passow JE, Pucci V, Ma B, Shumway SD, Elmquist WF, Agar NY, Sarkaria JN.

Clin Cancer Res. 2015 Apr 15;21(8):1916-24. doi: 10.1158/1078-0432.CCR-14-2588. Epub 2015 Jan 21.

14.

A phase 1 trial of ABT-510 concurrent with standard chemoradiation for patients with newly diagnosed glioblastoma.

Nabors LB, Fiveash JB, Markert JM, Kekan MS, Gillespie GY, Huang Z, Johnson MJ, Meleth S, Kuo H, Gladson CL, Fathallah-Shaykh HM.

Arch Neurol. 2010 Mar;67(3):313-9. doi: 10.1001/archneurol.2010.16.

PMID:
20212229
15.

Acquired resistance to combination treatment with temozolomide and ABT-888 is mediated by both base excision repair and homologous recombination DNA repair pathways.

Liu X, Han EK, Anderson M, Shi Y, Semizarov D, Wang G, McGonigal T, Roberts L, Lasko L, Palma J, Zhu GD, Penning T, Rosenberg S, Giranda VL, Luo Y, Leverson J, Johnson EF, Shoemaker AR.

Mol Cancer Res. 2009 Oct;7(10):1686-92. doi: 10.1158/1541-7786.MCR-09-0299. Epub 2009 Oct 13.

16.

PTEN loss compromises homologous recombination repair in astrocytes: implications for glioblastoma therapy with temozolomide or poly(ADP-ribose) polymerase inhibitors.

McEllin B, Camacho CV, Mukherjee B, Hahm B, Tomimatsu N, Bachoo RM, Burma S.

Cancer Res. 2010 Jul 1;70(13):5457-64. doi: 10.1158/0008-5472.CAN-09-4295. Epub 2010 Jun 8.

17.

In vitro and in vivo radiosensitization of glioblastoma cells by the poly (ADP-ribose) polymerase inhibitor E7016.

Russo AL, Kwon HC, Burgan WE, Carter D, Beam K, Weizheng X, Zhang J, Slusher BS, Chakravarti A, Tofilon PJ, Camphausen K.

Clin Cancer Res. 2009 Jan 15;15(2):607-12. doi: 10.1158/1078-0432.CCR-08-2079.

18.

Acquired resistance to temozolomide in glioma cell lines: molecular mechanisms and potential translational applications.

Zhang J, Stevens MF, Laughton CA, Madhusudan S, Bradshaw TD.

Oncology. 2010;78(2):103-14. doi: 10.1159/000306139. Epub 2010 Mar 31.

PMID:
20357518
19.

Induction of MGMT expression is associated with temozolomide resistance in glioblastoma xenografts.

Kitange GJ, Carlson BL, Schroeder MA, Grogan PT, Lamont JD, Decker PA, Wu W, James CD, Sarkaria JN.

Neuro Oncol. 2009 Jun;11(3):281-91. doi: 10.1215/15228517-2008-090. Epub 2008 Oct 24.

20.

Efficacy of PARP Inhibitor Rucaparib in Orthotopic Glioblastoma Xenografts Is Limited by Ineffective Drug Penetration into the Central Nervous System.

Parrish KE, Cen L, Murray J, Calligaris D, Kizilbash S, Mittapalli RK, Carlson BL, Schroeder MA, Sludden J, Boddy AV, Agar NY, Curtin NJ, Elmquist WF, Sarkaria JN.

Mol Cancer Ther. 2015 Dec;14(12):2735-43. doi: 10.1158/1535-7163.MCT-15-0553. Epub 2015 Oct 5.

Supplemental Content

Support Center